SCHEMBL3744660

SCHEMBL3744660

CC(C)(C(=O)O)C1=CC2(CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.49
MAPT P10636 2/20 0.48
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 3/20 0.43
MEN1 O00255 3/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
CNR1 P21554 1/20 0.43
GAA P10253 1/20 0.43
OXTR P30559 1/20 0.43
CYP2D6 P10635 1/20 0.42
CCR1 P32246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757096 0.88 HSD11B1 (0.53) HSD11B1KMT2AALDH1A1POLBMEN1
SCHEMBL3747452 0.87 POLB (0.49) HSD11B1MAPTKMT2AALDH1A1POLB
SCHEMBL3744639 0.80 HSD11B1 (0.47) HSD11B1MAPTKMT2AALDH1A1POLB
SCHEMBL3744806 0.79 HSD11B1 (0.48) HSD11B1MAPTKMT2AALDH1A1POLB
SCHEMBL13849267 0.78 OXTR (0.32) HSD11B1KMT2ATSHRCYP2C19SMN1; SMN2
SCHEMBL3749431 0.76 APP (0.45) HSD11B1KMT2AALDH1A1POLBMEN1
SCHEMBL3742451 0.76 KMT2A (0.46) HSD11B1MAPTKMT2AALDH1A1POLB
SCHEMBL3752150 0.74 POLB (0.50) HSD11B1KMT2AALDH1A1POLBMEN1
SCHEMBL13081500 0.74 SMN1; SMN2 (0.45) HSD11B1MAPTKMT2AALDH1A1POLB
SCHEMBL13081503 0.73 PKM (0.47) HSD11B1KMT2AALDH1A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298368-A1 ANTAGONISTS OF PGD2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-20100298368-A1 ANTAGONISTS OF PGD2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-20100298368-A1 ANTAGONISTS OF PGD2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298368-A1 ANTAGONISTS OF PGD2 RECEPTORS PTGDR2, PTGDR, LTB4R2 HSD11B1 442/4885MAPT 4735/4885KMT2A 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.